Rui Morais

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Role of Peroral Cholangioscopy for Diagnosis and Staging of Biliary Tumors

Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis